No Data
Form 144 | Ligand Pharmaceuticals(LGND.US) Officer Proposes to Sell 3.87 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 12, $LIGAND PHARMACEUTICAL INC(LGNXZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNYZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNZZ.US)$、$LIGAND PHARMACEUTICAL INC(LGNDZ.US)$、$Ligand
10-Q: Q3 2024 Earnings Report
8-K: Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
LIGAND PHARMACEUTICAL INC (LGNZZ.US) will release its financial report before the market opens on November 7th.
$LIGAND PHARMACEUTICAL INC (LGNZZ.US) will release its financial report before the market opens on November 7th. Investors are advised to pay attention. Futubull Reminder: 1. There is no strict requirement for the accounting year division time for companies listed on the Hong Kong and US stock markets, it is completely determined by the enterprise itself. Therefore, each financial report period can serve as the company's annual report deadline, and the fiscal year will not be based on the calendar year. 2. Generally, the company will hold a financial report meeting on the above-mentioned financial report release date or on nearby dates, where the company management will discuss the latest quarterly financial data and operational situation.
10-Q: Q2 2024 Earnings Report
8-K: Ligand Reports Second Quarter 2024 Financial Results
No Data